Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)

12 Months Ended

Dec. 31, 2020

Acquisition of Assets [Abstract]

Schedule of Total Consideration Paid

The total consideration paid was $51.6 million and consisted of (in thousands, except share amounts):

Fair value of 4,589,771 Aquinox common stock	$	15,055
Fair value of 101,927 Aquinox convertible preferred stock	33,432
Cash consideration for fractional shares	5
Transaction costs	3,086
Total consideration	$	51,578

Summary of the Assets Acquired and Liabilities Assumed

The following table summarizes the assets acquired and liabilities assumed (in thousands):

Assets acquired:
Cash and cash equivalents	$	3,282
Receivables, prepayments and deposits	560
Property and equipment	1,034
In-process research and development	47,716
Intangible asset	659
Total assets acquired	53,251
Liabilities assumed:
Accounts payable and other liabilities	1,472
Financing lease liability	201
Total liabilities assumed	1,673
Total consideration	$	51,578